Repros data highlights pain relief in Proellex trial

An interim analysis of mid-stage data on Repros' lead therapy Proellex revealed a statistically significant reduction in pain among women suffering from endometriosis. There were no significant differences in response to either the 25 mg or 50 mg dose of the drug and researchers say that most side effects were mild.

- read the release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.